鸟类GCGR介导的连续脂肪利用为肥胖治疗提供了前景
Chang Zhang1,2,3, Xue Wang1,2, Chenxi Feng1,2
1Department of High Altitude Medicine, Center for High Altitude Medicine, National Clinical Research Center for Geriatrics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Nature communications
|November 29, 2025
概括
鸟类拥有快速脂肪利用的独特机制,涉及脂肪细胞中高水平的葡萄糖受体 (GCGR). 这种鸟类的GCGR促进脂肪动员和持续减肥,为人类肥胖提供潜在的治疗策略.
科学领域:
- 代谢调节 代谢调节 代谢调节
- 比较生理学比较生理学
- 肥胖研究的研究.
背景情况:
- 人类肥胖是一个主要的全球健康问题,在脂肪质量损失和维护方面存在挑战.
- 鸟类表现出了显著的代谢适应性,通过高效的脂肪利用来维持低脂肪量.
- 这种鸟类代谢适应的生理基础长期以来一直是个.
研究的目的:
- 研究鸟类快速脂肪利用背后的分子机制.
- 探索葡萄糖受体 (GCGR) 在鸟类脂肪细胞中的作用.
- 评估鸟类类GCGR活性对哺乳动物肥胖症的治疗潜力.
主要方法:
- 跨物种单核RNA测序用于分析鸟类和其他脊椎动物脂肪组织中的基因表达.
- 在肥胖小鼠的白色脂肪组织中表达鸟类GCGR和构成性活跃的人类GCGR变体 (GCGR H339R).
- 对转基因小鼠的脂肪动员,体重变化和食物摄入量进行评估.
主要成果:
- 与其他脊椎动物相比,鸟类脂肪细胞表现出明显更高的GCGR表达.
- 鸟类GCGR促进了快速的脂肪利用,有助于维持鸟类的低体重.
- 在肥胖小鼠中表达鸟类GCGR或人类GCGRH339R促进了脂肪的调动和持续的体重减轻,部分是通过减少食物摄入.
结论:
- 鸟类GCGR是鸟类观察到的独特快速脂肪利用机制的关键因素.
- 这种鸟类GCGR通路为打击人类肥胖提供了潜在的新型治疗点.
- 构成性活跃的GCGR变体在促进肥胖的哺乳动物模型中的减肥方面表现出有效性.
相关概念视频
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
225
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
225
Drug Dosing: Obese Patients
202
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
202
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
161
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
161
Overview of Fatty Acid Metabolism
36.2K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
36.2K
Regulation of Metabolism
11.4K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
11.4K


